Figure 5.

Pharmacology of AAVCOVID vaccines in mice

(A) Quantification of vector genome copies (DNA, genome copies/diploid genome or gc/dg) in the right gastrocnemius (right gastroc) or injection site, left gastrocnemius (left gastroc) or contralateral muscle, liver, and spleen on weeks 1, 4, 8, and 16 after the administration of 10¹¹ gc of AC1 or AC3 in C57BL/6 animals (n ≥ 6, 3–5/gender). Horizontal dotted lines indicate background levels for right and left gastrocnemius muscles. Liver and spleen had not detectable background.

(B) Quantification of transgene expression (RBD copies/GAPD copies or RBD cp/GAPDH) in the right gastrocnemius muscle.

(C) Quantification of expression (RBD copies/GAPD copies or RBD cp/GAPDH) in the injection site (right gastroc), contralateral muscle (left gastroc), liver and spleen on week 16.

(D and E) SARS-CoV-2 RBD-binding antibody titer 29-week follow-up in BALB/c mice (n ≥ 9) vaccinated with 10¹⁰ gc of AC1 and AC3 on week 0 and revaccinated with 10¹¹gc of AAV1-S (open circles) or diluent (solid circles) on week 26.

(E) Pseudovirus neutralizing titers in animals described in (D) before and after the boost with AAV1-S.

(A–E) Data are represented as mean ± SD. (D and E) Student’s t test. ^∗p < 0.05, ^∗∗p < 0.01.